I期临床-话题@MedSci

#I期临床#

570篇内容 | 7046人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=49, createdTime=2020-09-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653116, encodeId=6b7616531165a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, objectType=article, longId=202926, objectId=e79820292602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79820292602, replyNumber=0, likeNumber=72, createdTime=2021-07-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79820292602, moduleTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79820292602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653126, encodeId=60b116531261a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, objectType=article, longId=203553, objectId=aa6a203553c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6a203553c0, replyNumber=0, likeNumber=77, createdTime=2021-05-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6a203553c0, moduleTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6a203553c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, objectType=article, longId=191301, objectId=64bf1913012b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64bf1913012b, replyNumber=0, likeNumber=0, createdTime=2020-05-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64bf1913012b, moduleTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64bf1913012b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653059, encodeId=70171653059a5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, objectType=article, longId=197968, objectId=d9bf19e9686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf19e9686d, replyNumber=0, likeNumber=61, createdTime=2021-05-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf19e9686d, moduleTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf19e9686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653046, encodeId=0a80165304680, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, objectType=article, longId=196771, objectId=6ae3196e71e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae3196e71e3, replyNumber=0, likeNumber=66, createdTime=2020-11-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae3196e71e3, moduleTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae3196e71e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652997, encodeId=6070165299e45, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=64, createdTime=2020-11-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652965, encodeId=2e6f16529657a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=64, createdTime=2020-02-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653002, encodeId=a6f31653002e7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=65, createdTime=2020-08-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653014, encodeId=8d381653014b4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, objectType=article, longId=192743, objectId=597a192e43e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597a192e43e8, replyNumber=0, likeNumber=69, createdTime=2020-07-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597a192e43e8, moduleTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597a192e43e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652995, encodeId=85e316529950a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062, objectType=article, longId=189174, objectId=b42d1891e483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b42d1891e483, replyNumber=0, likeNumber=79, createdTime=2021-02-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b42d1891e483, moduleTitle=武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b42d1891e483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653005, encodeId=9eb01653005fa, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=132, createdTime=2021-01-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652966, encodeId=50db16529664a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%, objectType=article, longId=184847, objectId=ab3518484e02, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab3518484e02, replyNumber=0, likeNumber=74, createdTime=2020-04-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab3518484e02, moduleTitle=阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab3518484e02)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653082, encodeId=e019165308229, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, objectType=article, longId=200167, objectId=7b7b20016e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7b20016e1e, replyNumber=0, likeNumber=61, createdTime=2021-06-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7b20016e1e, moduleTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7b20016e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652960, encodeId=834916529605c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, objectType=article, longId=183284, objectId=b20218328463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b20218328463, replyNumber=0, likeNumber=70, createdTime=2020-10-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b20218328463, moduleTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b20218328463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653086, encodeId=3b67165308658, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, objectType=article, longId=200591, objectId=c78820059127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78820059127, replyNumber=0, likeNumber=55, createdTime=2021-04-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78820059127, moduleTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78820059127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653077, encodeId=711216530e779, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, objectType=article, longId=199921, objectId=e4ad199921fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ad199921fd, replyNumber=0, likeNumber=60, createdTime=2020-11-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ad199921fd, moduleTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ad199921fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653021, encodeId=beb416530211a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, objectType=article, longId=193802, objectId=898d1938022e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898d1938022e, replyNumber=0, likeNumber=47, createdTime=2020-12-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898d1938022e, moduleTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898d1938022e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653092, encodeId=65a31653092fd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物, objectType=article, longId=201294, objectId=651520129438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=651520129438, replyNumber=0, likeNumber=66, createdTime=2020-12-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=651520129438, moduleTitle=Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=651520129438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652988, encodeId=40ec1652988aa, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, objectType=article, longId=187590, objectId=c62918e5909e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62918e5909e, replyNumber=0, likeNumber=64, createdTime=2020-04-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62918e5909e, moduleTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62918e5909e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-09-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床

2021-07-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%

2021-05-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

2020-05-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著

2021-05-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著

2020-11-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-11-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2020-02-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-08-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功

2020-07-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062

2021-02-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2021-01-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%

2020-04-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启

2021-06-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景

2020-10-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果

2021-04-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究

2020-11-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究

2020-12-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物

2020-12-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

通用型流感疫苗M-001的II期临床试验取得积极结果

2020-04-22

科室
- - 订阅+
  - 更多科室
工具
服务